A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

[1]  High-performance Liquid Chromatography/Tandem Mass Spectrometry , 2020, Definitions.

[2]  C. Peterfy,et al.  Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial , 2019, Arthritis & rheumatology.

[3]  Xiaohu Zhang,et al.  Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis , 2019, Cell Death & Disease.

[4]  P. Emery,et al.  Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study , 2019, The Lancet.

[5]  R. Landewé,et al.  LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS , 2019, Oral Presentations.

[6]  S. Moon,et al.  RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis , 2019, Journal of Translational Medicine.

[7]  Q. Shi,et al.  Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice. , 2019, Blood.

[8]  H. Genant,et al.  The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group , 2017, The Journal of Rheumatology.

[9]  P. A. Harris,et al.  Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers , 2017, Pharmacology research & perspectives.

[10]  C. Wijbrandts,et al.  Prediction of Response to Targeted Treatment in Rheumatoid Arthritis , 2017, Mayo Clinic proceedings.

[11]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[12]  Michelle C. Schaeffer,et al.  Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. , 2017, Journal of medicinal chemistry.

[13]  I. McInnes,et al.  Rheumatoid arthritis , 2016, The Lancet.

[14]  M. Dougados,et al.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study , 2016, Annals of the rheumatic diseases.

[15]  Michelle C. Schaeffer,et al.  Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase , 2015, Cell Death Discovery.

[16]  J. Casanova,et al.  Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia , 2015, The Journal of experimental medicine.

[17]  Junying Yuan,et al.  Necroptosis in health and diseases. , 2014, Seminars in cell & developmental biology.

[18]  M. Pasparakis,et al.  Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis , 2014, Proceedings of the National Academy of Sciences.

[19]  P. Riel.  The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). , 2014 .

[20]  Shuo Yang,et al.  RIP kinases: key decision makers in cell death and innate immunity , 2014, Cell Death and Differentiation.

[21]  Michelle C. Schaeffer,et al.  Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. , 2014, Journal of immunology.

[22]  Junying Yuan,et al.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death , 2013, Nature Reviews Molecular Cell Biology.

[23]  B. Wyman,et al.  Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. , 2013, Arthritis and rheumatism.

[24]  M. Xie,et al.  TAK1 Is Essential for Osteoclast Differentiation and Is an Important Modulator of Cell Death by Apoptosis and Necroptosis , 2012, Molecular and Cellular Biology.

[25]  E. Lee,et al.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.

[26]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[27]  H. Hase,et al.  NEMO Inhibits Programmed Necrosis in an NFκB-Independent Manner by Restraining RIP1 , 2012, PloS one.

[28]  P. Emery.  Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. , 2012, Rheumatology.

[29]  C. Peterfy,et al.  Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI , 2012, Arthritis Research & Therapy.

[30]  J. French,et al.  A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. , 2012, Arthritis and rheumatism.

[31]  M. Kool,et al.  A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis , 2011, Nature Genetics.

[32]  Anthony W. Purcell,et al.  Linear ubiquitination prevents inflammation and regulates immune signalling , 2011, Nature.

[33]  P. Tak,et al.  Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials , 2010, Annals of the rheumatic diseases.

[34]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[35]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[36]  Désirée van der Heijde,et al.  A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. , 2007, Arthritis and rheumatism.

[37]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[38]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[39]  B. Bresnihan,et al.  The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. , 2000, Arthritis and rheumatism.

[40]  P. Elliott,et al.  Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Baldwin,et al.  NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[43]  J. Fries,et al.  The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. , 2003, The Journal of rheumatology.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[45]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.